Literature DB >> 31162548

MiR-137's Tumor Suppression on Prolactinomas by Targeting MITF and Modulating Wnt Signaling Pathway.

Cao Lei1, Guo Jing2, Wang Jichao3, Lou Xiaohui2, Qiuyue Fang2, Gao Hua2, Miao Yazhou2, Yazhou Zhang2,4.   

Abstract

CONTEXT: Prolactinomas are the most common functional pituitary adenomas; the aggressive tumors still present challenge to clinicians. Aberrant expression of miRNAs has been functionally associated with prolactinomas.
OBJECTIVE: Here we explored the role of miR-137 on the proliferation, invasion, and apoptosis of prolactinomas and its possible mechanism.
RESULTS: Low expression of miR-137 was correlated with the invasive behavior of human prolactinomas and predicted high recurrence. MiR-137 inhibited cell proliferation, invasion, and survivals of MMQ and GH3 cells and reduced tumor volume in F344 rat prolactinomas. The luciferase reporter assay confirmed that microphthalmia-associated transcription factor (MITF) was the direct target of miR-137. In addition, miR-137 mimics could inhibit MITF expression in vivo and in vitro. Upregulation of MITF expression promoted cell proliferation, invasion, and survivals and reversed the antitumor effect of miR-137 in vivo and in vitro. Furthermore, miR-137 could also upregulate wnt-inhibitory factor-1 and inhibit nuclear translocation of β-catenin. Upregulation of wnt-inhibitory factor-1 with decitabine can enhance the inhibition on cell proliferation of miR-137. A glycogen synthase kinase-3 inhibitor, SB 216763, promoted cell proliferation by upregulation of total/cytoplasmic/nuclear β-catenin and reversed tumor suppression of miR-137 mimics.
CONCLUSIONS: Our data suggest that miR-137 possesses a tumor invasive suppressor function with a prognostic value in prolactinomas by targeting MITF and modulating Wnt-β-catenin signaling pathway.
Copyright © 2019 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31162548     DOI: 10.1210/jc.2018-02544

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Functional Screen for microRNAs Suppressing Anchorage-Independent Growth in Human Cervical Cancer Cells.

Authors:  Angelina Huseinovic; Annelieke Jaspers; Annina P van Splunter; Hanne Sørgård; Saskia M Wilting; Dorian R A Swarts; Ida H van der Meulen; Victor W van Beusechem; Renée X de Menezes; Renske D M Steenbergen
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

2.  The SF3B1R625H mutation promotes prolactinoma tumor progression through aberrant splicing of DLG1.

Authors:  Jing Guo; Chuzhong Li; Qiuyue Fang; Yulou Liu; Dawei Wang; Yiyuan Chen; Weiyan Xie; Yazhuo Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-01-17

3.  Serum MicroRNA-137 Serves as a Novel Biomarker for Cerebral Atherosclerosis Diagnosis and Cerebrovascular Event Prediction.

Authors:  Jingjing Xuan; Meiling Shang; Xuelian Li
Journal:  J Cardiovasc Pharmacol       Date:  2021-06-01       Impact factor: 3.271

Review 4.  The Emerging Role of Non-Coding RNAs in Pituitary Gland Tumors and Meningioma.

Authors:  Soudeh Ghafouri-Fard; Atefe Abak; Bashdar Mahmud Hussen; Mohammad Taheri; Guive Sharifi
Journal:  Cancers (Basel)       Date:  2021-11-28       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.